Measuring medication adherence in patients with schizophrenia is diffi cult and lacks a gold standard. Consequently, a great number of diff erent methods and instruments have been proposed. Although it has been assumed that they all measure medication adherence, this study demonstrates that instruments diff er signifi cantly. Using data from an international multisite study (N=329), we found that 3 questionnaires, designed to measure medication adherence and typical for instruments used in studies in patients with schizophrenia, do not agree in labeling patients as non-adherent. Further, they seem not to measure the same trait, are related to diff erent established risk factors of nonadherence, and are only weakly related to these established risk factors of non-adherence. 
Introduction
Non-adherence or poor adherence is a major concern in the treatment of chronic conditions such as schizophrenia. It places patients at risk for exacerbation of symptoms, care needs, and hospitalization with major social and economic consequences (AyusoGutierrez & del Rio Vega, 1997; Weiden & Olfson, 1995) . Although this has been known for several decades and studied extensively, clinicians still face a large number of non-adherent patients and do not make consistent use of evidence based adherence interventions (Ostenberg & Blaschke, 2005) .
A vast literature has been published on this topic and a wide variety of instruments and methods are used to measure medication adherence (Velligan et al., 2006) . It is unknown how these diff erent measures of adherence aff ect study results. Th ey at least make comparisons between studies problematic. Th is is particularly relevant in studies that try to determine (non)adherence rates, detect risk factors for non-adherence, and establish effi cacy of adherence interventions. Not surprisingly non-adherence rates reported in studies vary considerably. Cramer and Rosenheck (1998) found non-adherence rates ranging from 24% to 90%. Lacro et al. (2002) in their systematic review found nonadherence rates ranging from 4% to 72% while others concluded that a mean of 40% to 60% of patients with schizophrenia are believed to not adhere to their prescribed medication regimen (Nose et al., 2003; Young et al., 1986) . Systematic reviews on risk factors for non-adherence in patients with schizophrenia show a consistent infl uence of certain variables (insight and therapeutical alliance, for example), while study results for other variables such as age, gender, marital status, duration of illness, etc., are too inconsistent to draw a conclusion regarding their infl uence on adherence behavior (Lacro et al., 2002; Oehl et al., 2000; Perkins, 2002; Pinikahana et al., 2002) . Although it is unknown what causes these discrepancies, it has been argued that they might be attributed to diff erent methods and instruments used to measure adherence, a problem which is not restricted to adherence measurements in schizophrenia (Nichol et al., 1999; Osterberg & Blaschke, 2005; Velligan et al., 2006) .
Although the concept of medication adherence, defi ned as the degree to which medication is taken as prescribed, is relatively simple, measuring adherence behavior clearly is not. Adherence assessments can be divided in objective and subjective measures.
Objective measures are blood, urine or hair concentrations, pharmacy records and electronic pill counts. Subjective measures rely on assessments made by the patient or a closely involved person such as a clinician, nurse, or relative using questionnaires or binnenwerk m kikkert.indd 77 binnenwerk m kikkert.indd 77 9-1-2010 18:35:18 9-1-2010 18:35:18 interviews. In self-reports, patients are asked to rate their own adherence behavior or answer questions directly or indirectly related to medication use.
Reports from others usually rely on observed behavior such as clinical response, medication refusal, missed doses, regularity of visits, etc. Some studies combine a number of these methods to assess adherence rates. Lam et al. (2003) compared 3 diff erent measures of adherence in patients with schizophrenia (plasma levels, pill count, and selfreport) and found a remarkable poor agreement ranging from 0.17 to 0.28. In this study we will focus on the agreement of 3 adherence measures which are more similar in their approach.
In schizophrenia research approximately 75% of all studies rely on subjective measure (Velligan et al., 2006) . Objective measures are often too complex, invasive, costly, or time-consuming. Th ese subjective measures are, however, often poorly described, not validated, and are susceptible to error, misinterpretation, or distortion (Kane, 1983; Nichol et al., 1999; Nose et al., 2003; Osterberg & Blaschke, 2005; Velligan et al., 2006) .
Consequently, for the majority of instruments it is not known how validly they measure medication adherence. In the literature study, results are nevertheless interpreted as if they measured the same concept. If, however, the diff erent instruments measure diff erent concepts, this would partly explain between-study variability in fi ndings and conclusions.
In this article, we will explore 3 subjective adherence instruments (1 clinician rated and 2 patient rated) frequently used in adherence studies in schizophrenia. We will examine: (a) to what extent these instruments agree in labeling patients as non-adherent, (b) to what extent these instruments measure the same concept, and (c) how they are related to established risk factors for non-adherence.
Methods

Study Design
Th is study uses baseline data from the Quality of Life Following Adherence Th erapy for People Disabled by Schizophrenia and their Carers (QUATRO) study, an international randomized controlled trial assessing the effi cacy of Adherence Th erapy in patients with schizophrenia.
All patients that fulfi lled the inclusion criteria and gave written informed consent completed a number of questionnaires and were interviewed before randomization and start of the adherence intervention (Gray et al., 2006 
Adherence Instruments
Subjective measures diff er greatly among studies. Of-ten unspecifi ed and ad hoc measures are used (Velligan et al., 2006) . Only a limited number of standardized and established instruments are available. None of them is considered a (gold) standard. We selected 3 of these instruments for which some methodological evidence for the validity of these measures exists. Th e measures are typical for instruments used in studies in patients with schizophrenia and represent the way adherence is often operationalized: a self-report questionnaire (Medication Adherence Questionnaire, MAQ) (Morisky et al., 1986 ), a clinician rating of adherence (the Compliance Rating Scale, CRS) (Kemp & David, 1996) , and a selfreport questionnaire on drug attitudes (Drug Attitude Inventory, DAI) (Hogan et al., 1983) .
Th e MAQ consists of 4 yes/no questions and addresses ways in which patients may fail to take their prescribed medication: forgetting, carelessness, stopping the drug when they feel better, and/or stopping the drug because they believe it makes them feel worse (Morisky et al., 1986) . A higher score on the MAQ indicates less problems with medicine taking and good adherence behavior. Th e MAQ is applied to medical conditions including treatment for high blood pressure. Good internal consistency (α=0.61) have been demonstrated in a sample of 400 randomly selected patients who had been tested for high blood pressure. A factor analysis confi rmed the unidimensionality of the scale. in patients using tricylic antidepressants and found sensitivity scores ranging from 72%
to 84% and specifi city scores ranging from 55% to 74%, depending on MEMS cut off level. Shalansky et al. (2004) concluded that the MAQ was a reasonable instrument in detecting non-adherent patients after comparing the MAQ with prescription refi ll data in patients using chronic cardiovascular medications (Shalansky et al., 2004) .
Th e CRS is used to rate medication adherence on a 7-point scale. Th e CRS is scored by key workers. Complete refusal is scored 1, patients who partially refuse score 2, patients who reluctantly or passively accept treatment score 3, 4, or 5, and patients who moderately or actively accept treatment score 6 or 7. For each score a brief description of adherence behavior is provided in the questionnaire. Kemp et al. (1998) 
Risk Factors
We selected variables that have been identifi ed as risk factors of non-adherence in at least 3 of 5 systematic reviews published between 1997 and 2002 (Fenton et al., 1997; Lacro et al., 2002; Oehl et al., 2000; Perkins, 2002; Pinikahana et al., 2002) , and for which data were available. Given the attention they received in previous studies and their relevance for this topic, we decided to include side eff ects and medication characteristics in the analysis as well, although reports on their infl uence on adherence behavior are equivocal. 
Patient-Related Factors
Living situation was assessed with the European version of the Client Sociodemographic and Service Receipt Inventory (CSSRI-EU) (Chisholm et al., 2000) . As an indicator of medication supervision and degree of family involvement, items of the Involvement Evaluation Questionnaire (IEQ-EU) were used (Schene et al., 1998; van Wijngaarden et al., 2000) , assessing respectively how often the family ensured that the required medicine was taken, and their average weekly telephone or personal contact with the patient over the past 4 weeks. Th e IEQ-EU was completed by 166 carers, identifi ed by patients.
Remaining patients either did not consent to use carers information or could not identify a carer.
Perceived Benefi cial Medication Eff ects
Th e sum score of 4 DAI items was used as an indicator of perceived benefi cial eff ects.
Selected items refl ect feeling more relaxed, more normal, and having clearer thoughts when using medication and the feeling that medication can prevent one from getting sick.
Psychopathology and Level of Functioning
Level of psychopathology was assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Th e BPRS-E consists of 24 items measuring the following dimensions; positive symptoms, negative symptoms, depression/ anxiety, and disorganization (Ruggeri et al., 2005) . A higher score indicates more and more severe symptoms. Depression was assessed using the Calgary Depression Scale (CDS). Th e CDS is specifi cally developed for assessing depression in patients with schizophrenia by a 9-item structured interview (Addington et al., 1992) . A high summary score on the CDS indicates depression. Level of functioning was assessed using the Global Assessment of Functioning (GAF) (Jones et al., 1995) . A low score on the GAF indicates poor functioning. Two items from the Involvement Evaluation Questionnaire (IEQ-EU) were used as an indicator of substance abuse (van Wijngaarden et al., 2000) . On these items carers indicated how often, during the past 4 weeks, they guarded the patient from using too much alcohol, and illegal drugs. 
Insight
Insight was assessed with the expanded version of the Schedule for Assessment of Insight (SAI-E). Th e SAI-E is a semistructured interview measuring 3 dimensions of insight:
awareness of illness, relabeling of psychotic symptoms, and treatment compliance (David, 1990; Kemp et al., 1998) . Awareness of illness and relabeling of psychotic symptoms are based on self-report items. Th e subscale "treatment compliance" comprises 1 self-report item and 2 items in which the clinician rates the extent to which the patient accepts treatment and whether the patient unprompted asks for treatment. Th ese clinician rated items were, however, excluded because they overlap with the concept of adherence. Th e remaining self-report item, in which the patient is asked whether he thinks his condition, or the problem resulting from it, warrants treatment is used as an indicator of awareness of need for treatment. Higher scores indicate a higher level of insight.
Medication Side Eff ects
Th e Liverpool University Neuroleptic Side Eff ect Rating Scale (LUNSERS) was used to measure side eff ects consisting of 51 items (Day et al., 1995) . Day et al. (1995) validated the LUNSERS and found that it had a good testretest reliability (r=0.811, p<0.001) and concurrent validity against the UKU side eff ect rating scale for psychotropic drugs (UKU) (r=0.828, p<0.001).
Medication Type and Dose
Information on type and dosage of prescribed antipsychotic medication was provided by the patient's clinician. Th e prescribed daily dosage (PDD) was expressed as the proportion of the Defi ned Daily Dose (DDD) which is the international unit of drug utilization approved by the World Health Organization (WHO, 2003) .
Complexity of Medication Regimen
Total number of psychotropic drugs prescribed to a patient and how often they needed to be taken each day were used as an index of the complexity of the medication regimen.
Data Analysis
Criteria to label patients as either adherent or non-adherent were derived from the literature. For the MAQ, patients with a score ≤3 are defi ned as non-adherent (George et al., 2000; Morisky et al., 1986; Roth & Ivey, 2005 1998; Mutsatsa et al., 2003) . For the DAI, the sum of the negative items is subtracted from the sum of the positive items. If the resulting score is less than or equal to 0, patients are considered to be non-adherent (Hogan et al., 1983) .
In the remaining analysis we used continuous adherence scores to increase statistical power. Associations between interval and dichotomous variables were assessed with
Pearson product moment correlation. For ordinal variables a Spearman rank correlation was used. Correlations of subjectively rated variables were calculated using residual scores corrected for site diff erences. In Table 3 the level is set at 0.05. To partly correct for the increased family wise error in Table 4 as a result of multiple testing, we set the . level at 0.005.
Potential risk factors for non-adherence were categorized into domains. For each domain the relation between each risk factor and the 3 adherence instruments was presented. Th e overall variance in adherence scores explained by all risk factors within each domain, and the overall variance explained by all risk factors that were signifi cant at p≤0.005, were calculated and reported as the R 2 of a linear regression model.
Results
In the QUATRO study sample (N=409) eighty patients (20%) were in an inpatient setting (psychiatric or medical ward or in a 24-hour staff ed overnight facility). Th ese patients are excluded for further analysis to improve uniformity of our sample and to eliminate the eff ect of staff supervision on medication intake, which is often common practice in inpatient settings. Social and demographic characteristics are given in Table   1 . Our sample (N=329) was predominantly middle aged, single, unemployed, male, and chronic, which is typical for patients under the care of community mental health teams.
Of 284 patients, for which a score on all 3 instruments was available, overall nonadherence rates for the MAQ, CRS, and DAI are 54.9%, 20.4%, and 14.1% respectively.
Full consensus among the 3 instruments in labeling patients non-adherent is reached in approximately 4% of the patients. For the remaining 96% of the patients the 3 instruments give diff erent outcomes, 117 patients (41.2%) are non-adherent according to only 1, and 52 patients (18.3%) are non-adherent according to 2 of the 3 instruments (Table 2) . Although all 3 instruments were developed and used to detect non-adherent patients, Table 2 and Figure 1 demonstrate the limited overlap in patients identifi ed as nonadherent and show the diff erences in non-adherence rates. It is possible that this is due to using dichotomous scores that are based on diff erent cut off criteria or interpretations of non-adherence. We therefore performed a Pearson product moment correlation to examine the relation between the total scores on the instruments (Table 3) .
Again we found a poor overlap between the 3 instruments. Th e highest correlation coeffi cient was found between the CRS and the DAI (r=0.30; p<0.05), which is approximately equivalent to 9% explained variance. Th e low correlations do not exclude the possibility that one of these instruments is a valid measure of adherence behavior.
In this case this instrument should, however, be related to established risk factors for medication non-adherence (Table 4 ).
All correlation coeffi cients of the 3 instruments with established risk factors were relatively low. Risk factors for which we found a statistically signifi cant (though modest) c Sum score of DAI items 4, 7, 9 and 10. Correlation coeffi cient and R2 with the DAI is not calculated due to overlap d Analysis performed without substance abuse since IEQ-EU data was only available for a restricted number of patients. R2 for 'psychopathology and functioning' including all variables for the MAQ, CRS and DAI is respectively; 0.14 (N=151), 0.10 (N=145) and 0.14 (N=151)
e Risk factors included in analysis are: BPRS; depression/anxiety subscale, SAI-E; awareness of need for treatment f Risk factors included in analysis are: Perceived benefi cial medication eff ect, GAF, SAI-E; symptom relabelling and hypothetical contradiction, SAI-E; illness awareness, SAI-E; awareness of need for treatment g Risk factors included in analysis are: CDS; total score, GAF, SAI-E; symptom relabelling and hypothetical contradiction, SAI-E; illness awareness, SAI-E; awareness of need for treatment
For each domain, we assessed in a separate regression analysis the overall relationship between the risk factors pertaining to this domain and the 3 questionnaires. For all instruments explained variance was relatively low for all domains. An additional regression analysis was performed for each instrument incorporating only signifi cantly correlated risk factors over all domains. Th is resulted in an R 2 of 0.06 for the MAQ, a R 2 of 0.13 for the CRS, and a R 2 of 0.16 for the DAI.
Discussion
To date a wide variety of instruments and methods are used to measure adherence. Th e aim of this article was to examine the extent to which 3 subjective instruments (1 clinician rated and 2 patient rated), frequently used to measure adherence in schizophrenia, identify the same patients as non-adherent, measure the same concept, and how they relate to established risk factors for non-adherence. We found that there was little agreement among the instruments in labeling patients non-adherent, and they did not seem to measure the same concept. None of the instruments showed a clear relationship with established risk factors of non-adherence. Th erefore, it is diffi cult to decide which one, if any, is an appropriate measure of adherence.
Our fi ndings are highly relevant for studies that depend on a valid measure of medication adherence. Many diff erent methods and instruments have been used in studies and it has been assumed that they all measure the same trait. We demonstrate that it may not be justifi ed to assume this. We found poor overlap in 3 Th is study clearly indicates that conclusions regarding non-adherence rates or predictive factors of non-adherence can diff er considerably if they are based on any of these 3 instruments alone. Th erefore we conclude that the discrepancies found in literature are at least partly due to the heterogeneous methodology to measure medication adherence.
Although most variables used in this study have often been associated with adherence behavior, we were surprised by the weak relation with the adherence scales. Relatively few variables were signifi cantly correlated with the adherence scales but more important, the correlation coeffi cients were rather low. We were not able to explain more then 20% of variance in adherence scores, a result that is not uncommon in this type of research.
Such eff ect sizes are too small to be clinically relevant for the prediction or explanation of adherence behavior.
In this study we assumed that the adherence rates represent the degree of medication adherence and we expected at least some relation with established determinants of nonadherence. Given our results, we wonder if it is justifi ed to assume a linear relation between medication intake and adherence rates on these instruments. Possibly these instruments are sensitive to deviant adherence behavior or negative medication attitudes. Using cutoff criteria might therefore be useful in identifying patients who are likely, or at risk for being non-adherent. We do, however, not know which patients are completely nonbinnenwerk m kikkert.indd 88 binnenwerk m kikkert.indd 88 9-1-2010 18:35:19 9-1-2010 18:35:19 adherent, skip a dose once a while, or "only" have ambivalent thoughts about medication.
In research these instruments might therefore have limited value.
Concerning the low correlations between the adherence rates and risk factors in our study, there are 3 other issues we would like to raise. First, it has been argued that a patient's subjective perception of the eff ect of medication greatly infl uences adherence behavior (Adams & Scott, 2000; Marder 2005; Naber et al., 2005; Perkins et al., 2006) .
Although it is equally likely that established negative attitudes heighten sensitivity to adverse eff ects. Many variables, however, are based on clinician assessments. It might be more informative to focus on the patient's subjective ratings of perceived burden, family support, complexity of medication schedule, etc. (Ritsner et al., 2002) . Th e LUNSERS for instance asks patients to rate how much they experienced a specifi c side eff ect instead of how much it bothered them. Second, other studies demonstrate that some patients attribute benefi ts to their medication that are not directly related to their illness (Adams & Howe, 1993; Chan, 1984) . Patients might, for instance, fear that their children will be placed into care, fi nancial consequences because of losing paid work, or loss of social support if they do not take their medication as prescribed. Although we appreciate that it is diffi cult in quantitative studies to incorporate such specifi c risk factors, they might be nonetheless important in understanding patients' behavior (Adams & Howe, 1993; Kikkert et al., 2006) . Th ird, besides choosing relevant risk factors and a relevant perspective to measure them, one needs to consider what type of relation is expected. Th e statistical methods used in most studies assume linear relations. For some variables, however, it might be more appropriate to consider more complex relations or 2 directional relations. For example, adverse side eff ects might inhibit medication intake but are also likely to decline if medication intake is low, making it diffi cult, particularly in cross-sectional designs, to demonstrate a relation. Th is could perhaps also apply to other variables such as positive symptoms and quality of life, which might have a causal as well as a dependent relation with adherence.
According to a general accepted defi nition, patients are non-adherent if they do not fully follow medication prescription. Th is ignores a relevant distinction between completely and partly non-adherent patients. Skipping or forgetting a dose once every week is not the same as not taking medication at all. Grouping these patients together is likely to distort study results. Researchers should be more aware of the diff erence between measuring adherence behavior (degree of medication intake in reference to their prescription) and detecting non-adherent patients (identifying patients that do not fully comply with medication regimen or are at risk for being non-adherent). We would like to argue that methods used to measure medication adherence should indicate the actual proportion of used medication, and if the patient uses more than one agent, refers to the agent of interest. Th is will increase comparability among studies. It will also allow researchers to defi ne patients as non-adherent based on a pharmacological eff ective threshold; a minimum dose that will produce a clinically meaningful reduction of symptomatology. Th is may have more clinical relevance then the defi nition of nonadherence used up to date and may result in more valid study conclusions.
Although objective measures seem most appropriate to do this, they each have their limitations. Serum levels are invasive, costly, and require knowledge of individual pharmacokinetic characteristics. Pharmacy records can be informative but require an accurate administration system and only provide average adherence rates over longer periods of time (Rijcken et al., 2004) . In other fi elds electronic devices which record openings of a pill bottle container (MEMS) has been suggested as a new gold standard and seem to be a reliable indicator of medication adherence (Nichol et al., 1999; Osterberg & Blaschke, 2005) , practical in use in patients with schizophrenia (Diaz et al., 2001; Nakonezny & Byerly, 2006) . MEMS is, however, relatively expensive and is sensitive to patient errors (Arnet and Haefeli, 2000; Bova et al., 2005) . Researchers who are limited to using questionnaires might consider asking patients to report their own intake behavior over a limited period of time and combine this with information gathered from other sources such as a carer and/or key worker. Self-reports might, however, be susceptible to error and distortion. One of the main concerns is that patients might fi nd it diffi cult to be frank about their medication intake. Creating a confi dential, understanding, and nonjudgmental atmosphere is therefore important.
Th is study has limitations. Recruited patients met inclusion criteria including clinical instability in the previous 12 months. Although patient-related characteristics were representative for a population of patients with schizophrenia, this criterion might have aff ected our sample. Variables and adherence indexes used in this study were restricted by those used in the QUATRO study. For several variables we could not use appropriate measures but used proxies instead.
Th is study demonstrates that if we want to improve our understanding of adherence behavior in patients with schizophrenia, validated instruments are necessary that measure the degree of actual medication intake, as well as agreement among researchers to use them. 
